WAVE Life Sciences Ltd
WVE8.790USD
+0.160+1.85%
交易中 （美東）報價延遲15分鐘
1.37B總市值
虧損本益比TTM
關於 WAVE Life Sciences Ltd 公司
Wave Life Sciences Ltd. 是一家生物技術公司。該公司致力於釋放 RNA 藥物（寡核苷酸）或靶向核糖核酸 (RNA) 的藥物的潛力，以改變人類健康。其 RNA 藥物平臺 PRISMTM 結合了多種模式、化學創新和對人類遺傳學的深刻見解，從而帶來治療罕見和流行疾病的科學突破。其 RNA 靶向模式工具包包括 RNA 編輯、剪接、反義沉默和 RNA 干擾 (RNAi)，使公司能夠設計和持續交付最佳解決疾病生物學問題的候選藥物。其多元化的產品線包括杜氏肌營養不良症、Alpha-1 抗胰蛋白酶缺乏症和亨廷頓氏病的臨牀項目，以及肥胖症的臨牀前項目。這些項目包括 WVE-N531、WVE-006 和 WVE-003。該公司還在構建新型 A-to-I RNA 編輯寡核苷酸 (AIMers) 產品線。
公司簡介
公司代碼WVE
公司名稱WAVE Life Sciences Ltd
上市日期Nov 11, 2015
CEODr. Paul B. Bolno, M.D.
員工數量287
證券類型Ordinary Share
年結日Nov 11
公司地址7 Straits View
城市
上市交易所NASDAQ Global Market Consolidated
國家Singapore
郵編018936
電話6562363388
網址https://www.wavelifesciences.com/
公司代碼WVE
上市日期Nov 11, 2015
CEODr. Paul B. Bolno, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
25.00K
--
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
16.11K
--
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
16.11K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
16.11K
--
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
16.11K
--
Dr. Paul B. Bolno, M.D.
Dr. Paul B. Bolno, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher John Francis, Ph.D.
Dr. Christopher John Francis, Ph.D.
Senior Vice President - Corporate Development, Head - Emerging Areas
Senior Vice President - Corporate Development, Head - Emerging Areas
--
--
Dr. Gregory L. (Greg) Verdine, Ph.D.
Dr. Gregory L. (Greg) Verdine, Ph.D.
Director
Director
--
--
Dr. Peter Kolchinsky, Ph.D.
Dr. Peter Kolchinsky, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Chandra Vargeese, Ph.D.
Dr. Chandra Vargeese, Ph.D.
Chief Technology Officer, Head - Platform Discovery Sciences
Chief Technology Officer, Head - Platform Discovery Sciences
302.31K
--
Mr. Kyle Moran
Mr. Kyle Moran
Chief Financial Officer
Chief Financial Officer
25.00K
--
Mr. Ken Takanashi
Mr. Ken Takanashi
Independent Director
Independent Director
16.11K
--
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Chairman of the Board
Independent Chairman of the Board
16.11K
--
Ms. Aik Na Tan
Ms. Aik Na Tan
Independent Director
Independent Director
16.11K
--
Ms. Heidi L. Wagner, J.D.
Ms. Heidi L. Wagner, J.D.
Independent Director
Independent Director
16.11K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月15日 週四
更新時間: 5月15日 週四
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
11.44%
GSK plc
10.54%
Adage Capital Management, L.P.
7.87%
Maverick Capital, Ltd.
5.19%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
59.80%
持股股東
持股股東
佔比
RA Capital Management, LP
11.44%
GSK plc
10.54%
Adage Capital Management, L.P.
7.87%
Maverick Capital, Ltd.
5.19%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
59.80%
股東類型
持股股東
佔比
Investment Advisor
30.61%
Hedge Fund
23.74%
Investment Advisor/Hedge Fund
15.97%
Corporation
15.66%
Venture Capital
11.72%
Research Firm
1.66%
Individual Investor
0.59%
Pension Fund
0.31%
Bank and Trust
0.28%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
363
156.57M
98.38%
-1.61M
2025Q1
368
156.82M
101.38%
+1.16M
2024Q4
342
152.89M
100.27%
+6.14M
2024Q3
306
144.44M
97.59%
+25.71M
2024Q2
274
116.00M
94.13%
+429.46K
2024Q1
255
115.83M
95.69%
+2.66M
2023Q4
240
115.18M
98.42%
+19.70M
2023Q3
224
93.79M
97.86%
+5.83M
2023Q2
224
93.41M
97.80%
+7.66M
2023Q1
249
91.33M
96.13%
+7.12M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
18.20M
11.7%
--
--
Mar 31, 2025
GSK plc
16.78M
10.78%
--
--
Jun 06, 2025
Adage Capital Management, L.P.
12.52M
8.05%
+2.89M
+30.08%
Mar 31, 2025
Maverick Capital, Ltd.
8.26M
5.31%
+441.00
+0.01%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
5.28%
+200.47K
+2.50%
Mar 31, 2025
Driehaus Capital Management, LLC
6.36M
4.09%
-353.85K
-5.27%
Mar 31, 2025
Shin Nippon Biomedical Laboratories Ltd
5.71M
3.67%
--
--
Jun 06, 2025
M28 Capital Management LP
5.66M
3.64%
--
--
Mar 31, 2025
Emerald Advisers LLC
5.06M
3.26%
-29.02K
-0.57%
Mar 31, 2025
Kynam Capital Management LP
4.90M
3.15%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
1.41%
Global X Genomics & Biotechnology ETF
1.02%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.81%
iShares U.S. Pharmaceuticals ETF
0.39%
First Trust Multi-Manager Small Cap Opportunities ETF
0.21%
Franklin Genomic Advancements ETF
0.17%
iShares Micro-Cap ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比1.41%
Global X Genomics & Biotechnology ETF
佔比1.02%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.81%
iShares U.S. Pharmaceuticals ETF
佔比0.39%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0.21%
Franklin Genomic Advancements ETF
佔比0.17%
iShares Micro-Cap ETF
佔比0.16%
ProShares Ultra Nasdaq Biotechnology
佔比0.11%
Invesco Nasdaq Biotechnology ETF
佔比0.11%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
